HCWB实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases...

Stats
今日成交量	5 719.00
平均成交量	15 709.00
市值	50.31M
EPS	$-0.300 ( 2024-04-01 )
下一个收益日期	( $0 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.900
ATR14	$0.0450 (3.24%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-20	Wong Hing C	Buy	739 288	Common Stock
2024-02-20	Greene Rick S.	Buy	35 714	Common Stock
2024-02-20	Giles Lisa M.	Buy	35 715	Common Stock
2024-02-20	Garrett Scott T	Buy	142 858	Common Stock
2024-02-20	Flowers Lee	Buy	71 429	Common Stock

INSIDER POWER
92.28
Last 100 transactions
Buy: 3 866 595 \| Sell: 3 743 515

HCW Biologics Inc. 相关性

10 最正相关
BRKR	0.938
GRMN	0.933
IMGN	0.932
TRVI	0.927
EBIZ	0.926
FRPT	0.926
NXGN	0.926
STRL	0.926
APLT	0.925
BLU	0.924

10 最负相关
MFIN	-0.922
BCOR	-0.917
AMTBB	-0.905
TZPS	-0.903
SABR	-0.902
PEAR	-0.901
GLLI	-0.899
LCYAU	-0.894
VORB	-0.893
MCAA	-0.893

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

HCW Biologics Inc. 财务报表

Annual	2023
营收:	$2.84M
毛利润:	$-574 824 (-20.23 %)
EPS:	$-0.700

FY	2023
营收:	$2.84M
毛利润:	$-574 824 (-20.23 %)
EPS:	$-0.700

FY	2022
营收:	$6.72M
毛利润:	$2.59M (38.48 %)
EPS:	$-0.410

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.527

Financial Reports:

No articles found.

HCW Biologics Inc.

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.